Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

[1]  S. Kapur,et al.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use? , 2008, Schizophrenia bulletin.

[2]  J. Lieberman,et al.  The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[3]  D. Goldstein,et al.  Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study , 2008, Genetics in Medicine.

[4]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[5]  J. Os,et al.  Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions , 2008, Molecular Psychiatry.

[6]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[7]  Jacques Fellay,et al.  WGAViewer: software for genomic annotation of whole genome association studies. , 2008, Genome research.

[8]  Patrick F. Sullivan,et al.  Association of RGS2 and RGS5 variants with schizophrenia symptom severity , 2008, Schizophrenia Research.

[9]  N. Schork,et al.  Advances in endophenotyping schizophrenia , 2008, World psychiatry : official journal of the World Psychiatric Association.

[10]  P. Sullivan,et al.  Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia , 2008, Biological Psychiatry.

[11]  I. Grossman.  Routine pharmacogenetic testing in clinical practice: dream or reality? , 2007, Pharmacogenomics.

[12]  G. Reynolds.  The impact of pharmacogenetics on the development and use of antipsychotic drugs. , 2007, Drug discovery today.

[13]  J. Kennedy,et al.  Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. , 2007, The international journal of neuropsychopharmacology.

[14]  Michael E. Ragozzino,et al.  VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux , 2007, Neuropharmacology.

[15]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[16]  J. Lieberman,et al.  NCAM1 and Neurocognition in Schizophrenia , 2007, Biological Psychiatry.

[17]  J. Lieberman,et al.  AKT1 and Neurocognition in Schizophrenia , 2007, The Australian and New Zealand journal of psychiatry.

[18]  F. Drago,et al.  Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia , 2006, Brain Research.

[19]  Jürgen Gallinat,et al.  Variations in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) are Associated with Bipolar I Disorder , 2006, Neuropsychopharmacology.

[20]  J. Os,et al.  Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis , 2006, Schizophrenia Research.

[21]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[22]  D. Pascoe,et al.  Modifications of 5-HT4 receptor expression in rat brain during memory consolidation , 2005, Brain Research.

[23]  G. Reynolds,et al.  Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response , 2005, European Neuropsychopharmacology.

[24]  C. Montresor,et al.  MCP‐1 gene (SCYA2) and schizophrenia: A case‐control association study , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[25]  W. Fenton,et al.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia , 2004, Schizophrenia Research.

[26]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[27]  M. Egan,et al.  Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications , 2004, Biological Psychiatry.

[28]  J. Callicott,et al.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.

[29]  T. Lehtimäki,et al.  Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. , 2004, Pharmacogenetics.

[30]  Chih-Chiang Chiu,et al.  Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. , 2002, The American journal of psychiatry.

[31]  A. Malhotra,et al.  Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. , 2002, Psychiatric genetics.

[32]  R. Kerwin,et al.  Risperidone may induce mania , 2002, Psychopharmacology.

[33]  D. Rujescu,et al.  Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. , 2001, The American journal of psychiatry.

[34]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[35]  M. Alda,et al.  T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. , 1999, Journal of psychiatry & neuroscience : JPN.

[36]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[37]  Scott C Armstrong,et al.  Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. , 2006, Psychosomatics.

[38]  S. Kéri,et al.  Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.